Aralez Bio, a platform technology company with a proprietary enzymatic approach for designing and manufacturing noncanonical amino acids (ncAAs), announced the close of its oversubscribed $12 million Series A financing. The round was led by Spero Ventures with matched investment from Paladin Capital Group. Additional investors included Good Growth Capital, Astia Ventures, Heritage Medical Systems, Freeflow Ventures, Impact Science Ventures, Juniper, and Pineapple Group.

Aralez Bio's platform is expanding the amino acid toolbox 1000-fold, creating building blocks that drive next-generation products.